OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer

Daisuke Obinata, Daigo Funakoshi, Kenichi Takayama, Makoto Hara, Birunthi Niranjan, Linda Teng, Mitchell G. Lawrence, Renea A. Taylor, Gail P. Risbridger, Yutaka Suzuki, Satoru Takahashi, Satoshi Inoue

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)


Androgen and androgen receptor (AR) targeted therapies are the main treatment for most prostate cancer (PC) patients. Although AR signaling inhibitors are effective, tumors can evade this treatment by transforming to an AR-negative PC via lineage plasticity. OCT1 is a transcription factor interacting with the AR to enhance signaling pathways involved in PC progression, but its role in the emergence of the AR-negative PC is unknown. We performed chromatin immunoprecipitation sequencing (ChIP-seq) in patient-derived castration-resistant AR-negative PC cells to identify genes that are regulated by OCT1. Interestingly, a group of genes associated with neural precursor cell proliferation was significantly enriched. Then, we focused on neural genes STNB1 and PFN2 as OCT1-targets among them. Immunohistochemistry revealed that both STNB1 and PFN2 are highly expressed in human AR-negative PC tissues. Knockdown of SNTB1 and PFN2 by siRNAs significantly inhibited migration of AR-negative PC cells. Notably, knockdown of PFN2 showed a marked inhibitory effect on tumor growth in vivo. Thus, we identified OCT1-target genes in AR-negative PC using a patient-derived model, clinicopathologial analysis and an animal model.

Original languageEnglish
Article number6094
Number of pages13
JournalScientific Reports
Issue number1
Publication statusPublished - Dec 2022

Cite this